A woman who receives a radionuclide for diagnosis or therapy may excrete the compound in breast milk, thereby exposing a nursing infant to the compound. Certain steps must be taken before, during and after radionuclide exposure to reduce this risk.
Factors affecting decision:
(1) type of radiation emitted
(2) total dose administered
(3) half-life
(4) distribution into breast milk
(5) excretion mechanics
Radionuclide |
Duration of Radioactivity in Breast Milk |
copper-64 |
3 days |
gallium-67 |
2 weeks |
indium-111 |
20 hours |
iodine-123 |
36 hours |
iodine-125 |
12 days |
iodine-131, diagnostic |
2-14 days |
iodine-131, therapeutic |
variable, may be prolonged |
sodium |
4-5 days |
technetium-99m compounds |
15 hours to 3 days, depending on dose |
Steps to be taken by the mother:
(1) Prior to the exposure additional breast milk should be collected and frozen for use during the period when the radionuclide will be excreted. The average volume of breast milk produced per day is 750 m (Recommended Dietary Allowances, 10th Edition).
(2) The infant should receive either formula or frozen breast milk during the period that radionuclide is excreted.
(3) The woman should pump the breast during the period that the radionuclide is excreted, Usually this can be disposed of by flushing down into the sewer with water. However, if the level of radioactive material is high then the milk should be disposed of the Radiation Safety Officer.
(4) Prior to resumption of breast feeding the woman should be evaluated by the Radiation Safety Officer. A sample of breast milk may be tested for residual radioactive emissions.
Purpose: To evaluate a nursing mother who must receive a radionuclide and to instruct her in the care of her infant.
Specialty: Hematology Oncology
Objective: response to therapy
ICD-10: J70.0, J70.1, K52.0, K62.7, L58, T66, W88, W91, Z08.1,